Extracellular Vesicle-Based SARS-CoV-2 Vaccine
Messenger ribonucleic acid (RNA) vaccines are mainly used as SARS-CoV-2 vaccines. Despite several issues concerning storage, stability, effective period, and side effects, viral vector vaccines are widely used for the prevention and treatment of various diseases. Recently, viral vector-encapsulated...
Main Authors: | Yasunari Matsuzaka, Ryu Yashiro |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-02-01
|
Series: | Vaccines |
Subjects: | |
Online Access: | https://www.mdpi.com/2076-393X/11/3/539 |
Similar Items
-
Understanding the Molecular Actions of Spike Glycoprotein in SARS-CoV-2 and Issues of a Novel Therapeutic Strategy for the COVID-19 Vaccine
by: Yasunari Matsuzaka, et al.
Published: (2024-06-01) -
Advances in Purification, Modification, and Application of Extracellular Vesicles for Novel Clinical Treatments
by: Yasunari Matsuzaka, et al.
Published: (2022-12-01) -
Plant-Derived Extracellular Vesicles as a Delivery Platform for RNA-Based Vaccine: Feasibility Study of an Oral and Intranasal SARS-CoV-2 Vaccine
by: Margherita A. C. Pomatto, et al.
Published: (2023-03-01) -
Edible Plant-Derived Extracellular Vesicles for Oral mRNA Vaccine Delivery
by: Chiara Gai, et al.
Published: (2024-02-01) -
On the Relationship of Viral Particles and Extracellular Vesicles: Implications for Viral Vector Technology
by: Christoph Metzner, et al.
Published: (2021-06-01)